<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7402395\results\search\disease\results.xml">
  <result pre="the data. Abstract In December 2019, a novel coronavirus, named" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or (2019-nCoV) with"/>
  <result pre="data. Abstract In December 2019, a novel coronavirus, named Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or (2019-nCoV) with unknown"/>
  <result pre="Abstract In December 2019, a novel coronavirus, named Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2) or (2019-nCoV) with unknown origin"/>
  <result pre="In December 2019, a novel coronavirus, named Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2) or (2019-nCoV) with unknown origin spread"/>
  <result pre="unknown origin spread in Hubei province of China. The epidemic" exact="disease" post="caused by SARS-CoV-2 called coronavirus disease-19 (COVID-19). The presence"/>
  <result pre="ranging from asymptomatic/mild symptoms to severe illness and death. The" exact="viral infection" post="expanded internationally and WHO announced a Public Health Emergency"/>
  <result pre="from asymptomatic/mild symptoms to severe illness and death. The viral" exact="infection" post="expanded internationally and WHO announced a Public Health Emergency"/>
  <result pre="International Concern. To quickly diagnose and control such a highly" exact="infectious disease," post="suspicious individuals were isolated and diagnostic/treatment procedures were developed"/>
  <result pre="all, the characteristics of the virus, its pathogenicity, and its" exact="infectious" post="pathways must be well known. Thus, the main purpose"/>
  <result pre="this review is to provide an overview of this epidemic" exact="disease" post="based on the current evidence. Keywords Coronavirus COVID-19 SARS-CoV-2"/>
  <result pre="on the current evidence. Keywords Coronavirus COVID-19 SARS-CoV-2 2019-nCoV Viruses" exact="Epidemic" post="disease Background In December 2019, an outbreak of pneumonia"/>
  <result pre="the current evidence. Keywords Coronavirus COVID-19 SARS-CoV-2 2019-nCoV Viruses Epidemic" exact="disease" post="Background In December 2019, an outbreak of pneumonia with"/>
  <result pre="Viruses Epidemic disease Background In December 2019, an outbreak of" exact="pneumonia" post="with unknown origin began in Chinaâ€™s Hubei Province, raising"/>
  <result pre="ease of transmission. To quickly diagnose and control the highly" exact="infectious disease," post="suspected people were isolated and diagnostic/ therapeutic procedures were"/>
  <result pre="epidemiological and clinical data. After numerous studies, a novel severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the"/>
  <result pre="and clinical data. After numerous studies, a novel severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) was identified as the cause"/>
  <result pre="clinical data. After numerous studies, a novel severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) was identified as the cause of"/>
  <result pre="was identified as the cause of the disease, and the" exact="disease" post="was dubbed â€œcoronavirus-19â€³ (COVID-19) by Chinese Scientists [1, 2]."/>
  <result pre="and shortness of breath. Other reported symptoms are weakness, malaise," exact="respiratory" post="distress, muscle pain, sore throat, loss of taste and/or"/>
  <result pre="of breath. Other reported symptoms are weakness, malaise, respiratory distress," exact="muscle" post="pain, sore throat, loss of taste and/or smell [3]."/>
  <result pre="COVID-19 is based on clinical manifestations, molecular diagnostics of the" exact="viral" post="genome by RT-PCR, chest x-ray or CT scan, and"/>
  <result pre="clinical manifestations, molecular diagnostics of the viral genome by RT-PCR," exact="chest" post="x-ray or CT scan, and serology blood tests. The"/>
  <result pre="As the body requires time to respond to the antigenic" exact="viral" post="attack, symptoms may appear 2 to 14â€‰days after exposure"/>
  <result pre="to 14â€‰days after exposure to the virus. The window-period of" exact="viral" post="replication leads to false-negative results and problems in preventing"/>
  <result pre="is PCR tests, as a molecular diagnostic technique based on" exact="viral" post="genetic material that can diagnose an active COVID-19 infection."/>
  <result pre="PCR depends on the presence of a sufficient amount of" exact="viral" post="genome in the patient sample [6, 7] and the"/>
  <result pre="methods that able to detect the 2019-nCoV even in low" exact="viral" post="titers are fairly necessary. The other type is serological"/>
  <result pre="The other type is serological tests based on antibodies against" exact="viral" post="proteins. Serological tests identify people who have developed an"/>
  <result pre="the virus, especially IgM which is produced early after the" exact="infection" post="[8]. It seems that serological tests, along with PCR"/>
  <result pre="do not help diagnose and screen in early infection. After" exact="infection" post="with 2019-nCoV, it takes 2 weeks or more for"/>
  <result pre="detected [9]. Thus, early IgM/IgG antibody tests cannot detect active" exact="viral" post="shedding in early infection, and if an individual is"/>
  <result pre="infectious. In other words, due to the direct identification of" exact="viral" post="RNA, molecular tests are more sensitive than immune and"/>
  <result pre="sensitive than immune and serological tests in the diagnose of" exact="primary" post="infection and can accelerate early screening even during the"/>
  <result pre="than immune and serological tests in the diagnose of primary" exact="infection" post="and can accelerate early screening even during the incubation"/>
  <result pre="with a positive RT-PCR test and severe, mild, or asymptomatic" exact="infection" post="may still be prone to a second infection. Coronavirus"/>
  <result pre="is because of the spike [S] glycoprotein radiating from the" exact="viral" post="surface virus (Fig. 1). The S glycoprotein and the"/>
  <result pre="RaTG13. It has been reported that the beta-coronaviruses cause severe" exact="disease" post="while the alpha-coronaviruses cause asymptomatic or mildly symptomatic disease"/>
  <result pre="cause severe disease while the alpha-coronaviruses cause asymptomatic or mildly" exact="symptomatic" post="disease [15, 16]. 2019-nCoV is closely related to the"/>
  <result pre="severe disease while the alpha-coronaviruses cause asymptomatic or mildly symptomatic" exact="disease" post="[15, 16]. 2019-nCoV is closely related to the B"/>
  <result pre="lineage of the beta-coronaviruses, which are known to cause severe" exact="disease" post="and fatalities [17]. To determine amino acid sequence and"/>
  <result pre="and subsequently to predict their interactions to host cells, the" exact="complete" post="virus genome was sequenced and also was deposited in"/>
  <result pre="have revealed the outer membrane spike glycoprotein as the prime" exact="viral" post="adhesion factor interacts with host cell targets such as"/>
  <result pre="the SARS-CoV (2002â€&quot;2003) in China and with the Middle East" exact="Respiratory" post="Syndrome Coronavirus (2012) in Saudi Arabia for their zoonotic"/>
  <result pre="SARS-CoV (2002â€&quot;2003) in China and with the Middle East Respiratory" exact="Syndrome" post="Coronavirus (2012) in Saudi Arabia for their zoonotic transmission"/>
  <result pre="the host cell membrane. ACE2 is mainly distributed in the" exact="epithelial" post="cells of the lung and gastrointestinal tract. So, severe"/>
  <result pre="epithelial cells of the lung and gastrointestinal tract. So, severe" exact="infection" post="may occur in tissues with high expression levels of"/>
  <result pre="high expression levels of ACE2 including lung, intestine, kidney, and" exact="blood vessels" post="[25]. Using the Swiss-Model program 33, the three-dimensional structure"/>
  <result pre="RBD in other beta-coronaviruses, consists of a core and an" exact="external" post="subdomain (Fig. 2b-d). Interestingly, the similarity among the external"/>
  <result pre="an external subdomain (Fig. 2b-d). Interestingly, the similarity among the" exact="external" post="subdomain of RBD in 2019-nCoV with that in SARS-CoV"/>
  <result pre="those in the SARS-CoV-RBD [6, 26]. Pathogenesis of the 2019-nCoV" exact="Acute" post="2019-nCoV infections are very similar to seasonal flu with"/>
  <result pre="the SARS-CoV-RBD [6, 26]. Pathogenesis of the 2019-nCoV Acute 2019-nCoV" exact="infections" post="are very similar to seasonal flu with the most"/>
  <result pre="most common symptoms of fever, headache, shortness of breath, cough," exact="muscle" post="aches, and tiredness [1, 27]. The severity of the"/>
  <result pre="muscle aches, and tiredness [1, 27]. The severity of the" exact="disease" post="in most infected people is mild to moderate, and"/>
  <result pre="hospitalization. While patients with serious symptoms such as difficulty breathing," exact="chest" post="pain or pressure, and loss of speech or movement"/>
  <result pre="or movement need urgent medical attention. Other disorders seen in" exact="acute" post="conditions include hemoptysis, diarrhea, dyspnea, acute heart injuries, and"/>
  <result pre="Other disorders seen in acute conditions include hemoptysis, diarrhea, dyspnea," exact="acute" post="heart injuries, and ground-glass opacities. The lungs are the"/>
  <result pre="disorders seen in acute conditions include hemoptysis, diarrhea, dyspnea, acute" exact="heart" post="injuries, and ground-glass opacities. The lungs are the primary"/>
  <result pre="acute heart injuries, and ground-glass opacities. The lungs are the" exact="primary" post="site of 2019-nCoV infection. The chest CT of the"/>
  <result pre="The lungs are the primary site of 2019-nCoV infection. The" exact="chest" post="CT of the infected patients usually shows bilateral ground-glass"/>
  <result pre="infection. The chest CT of the infected patients usually shows" exact="bilateral" post="ground-glass opacity lesions in the posterior and peripheral lungs"/>
  <result pre="infected patients usually shows bilateral ground-glass opacity lesions in the" exact="posterior" post="and peripheral lungs that are reported as the characteristic"/>
  <result pre="usually shows bilateral ground-glass opacity lesions in the posterior and" exact="peripheral" post="lungs that are reported as the characteristic of 2019-nCoV"/>
  <result pre="peripheral lungs that are reported as the characteristic of 2019-nCoV" exact="pneumonia" post="[28]. Pathologic studies on biopsy samples of lung, liver,"/>
  <result pre="pneumonia [28]. Pathologic studies on biopsy samples of lung, liver," exact="and heart" post="obtained from death COVID-19 patients have revealed that the"/>
  <result pre="[28]. Pathologic studies on biopsy samples of lung, liver, and" exact="heart" post="obtained from death COVID-19 patients have revealed that the"/>
  <result pre="lung is the main affected tissue with pathological changes including" exact="hyperplasia" post="of type II pneumocytes, damage to the alveolar epithelial"/>
  <result pre="the main affected tissue with pathological changes including hyperplasia of" exact="type II" post="pneumocytes, damage to the alveolar epithelial cells, the formation"/>
  <result pre="including hyperplasia of type II pneumocytes, damage to the alveolar" exact="epithelial" post="cells, the formation of the hyaline membrane and diffuse"/>
  <result pre="alveolar epithelial cells, the formation of the hyaline membrane and" exact="diffuse" post="alveolar damage [29]. Thrombotic microangiopathy, significant accumulations of CD4+"/>
  <result pre="involved with the mentioned process [30]. Besides, the abundance of" exact="viral" post="RNA in neutrophils within the alveoli and the existence"/>
  <result pre="alveoli and the existence of some degenerated neutrophils indicate the" exact="viral infection" post="in these cells [31]. Megakaryocyte response and platelet production"/>
  <result pre="and the existence of some degenerated neutrophils indicate the viral" exact="infection" post="in these cells [31]. Megakaryocyte response and platelet production"/>
  <result pre="and platelet production have also been reported in H1N1 influenza" exact="infections" post="[32]. Multifocal hepatic necrosis, mild lymphocytic infiltration, sinusoidal dilation,"/>
  <result pre="COVID-19 patients with moderate to severe illness [33]. Mild myocardial" exact="hypertrophy" post="changes and focal fibrosis are tissue changes seen in"/>
  <result pre="moderate to severe illness [33]. Mild myocardial hypertrophy changes and" exact="focal" post="fibrosis are tissue changes seen in the heart biopsies"/>
  <result pre="changes and focal fibrosis are tissue changes seen in the" exact="heart" post="biopsies of death COVID-19 patients [29]. Therefore, the researchers"/>
  <result pre="researchers believe that effective therapy for COVID-19 should not be" exact="limited" post="only to the viral pathogen as a target, but"/>
  <result pre="therapy for COVID-19 should not be limited only to the" exact="viral" post="pathogen as a target, but also the microangiopathic and"/>
  <result pre="thrombotic effects of the virus, and body immune response to" exact="viral infection" post="must be considered in the disease management [34, 35]."/>
  <result pre="effects of the virus, and body immune response to viral" exact="infection" post="must be considered in the disease management [34, 35]."/>
  <result pre="immune response to viral infection must be considered in the" exact="disease" post="management [34, 35]. The human angiotensin-converting enzyme 2 (ACE2),"/>
  <result pre="enzyme 2 (ACE2), known as the major receptor for the" exact="viral" post="S protein provides the entry point for 2019-nCoV to"/>
  <result pre="DC-SIGN or L-SIGN or with their gene expression may inhibit" exact="viral" post="invasion. ACE2 is found in many types of cells"/>
  <result pre="in many types of cells and tissues, including the lungs," exact="blood vessels," post="heart, liver, kidneys, and gastrointestinal tract. It is also"/>
  <result pre="the nose, and mouth [36]. It is highly abundant in" exact="type 2" post="pneumocytes, the important cells located in alveoli, where oxygen"/>
  <result pre="more available Ang I which is changed into Ang II." exact="Increased" post="local Ang II levels damage blood vessel linings and"/>
  <result pre="been detected in lung tissue, especially in the membrane of" exact="pulmonary" post="epithelial cells [40]. In addition to the negative effect"/>
  <result pre="detected in lung tissue, especially in the membrane of pulmonary" exact="epithelial" post="cells [40]. In addition to the negative effect on"/>
  <result pre="lowers blood pressure, but causes contraction in the non-vascular smooth" exact="muscle" post="of the bronchi and intestines and may play a"/>
  <result pre="of COVID-19 disease. Both Prolylcarboxypeptidase and Prolylendopeptidase are lysosomal and" exact="cytosolic" post="peptidase, respectively, that have been mainly expressed in white"/>
  <result pre="and MERS-CoV from an animal to a human requires an" exact="intermediate" post="host such as palm civets for SARS-CoV and camels"/>
  <result pre="similarities between SARS-CoV and the 2019-nCoV, another animal as an" exact="intermediate" post="host is probably needed to transmit 2019-nCoV to humans."/>
  <result pre="needed to transmit 2019-nCoV to humans. If true, finding the" exact="intermediate" post="2019-nCoV host is vital to prevent interspecies transmission. In"/>
  <result pre="transmission. In this regard, pangolins have been suggested as an" exact="intermediate" post="host for 2019-nCoV, however, this assumption has not yet"/>
  <result pre="to a small number of cases that are identified locally." exact="Local" post="transmission shows the locations that have been reported as"/>
  <result pre="it cannot be said that it is completely 100% safe." exact="Intestinal" post="infection and the presence of 2019-nCoV in feces have"/>
  <result pre="cannot be said that it is completely 100% safe. Intestinal" exact="infection" post="and the presence of 2019-nCoV in feces have been"/>
  <result pre="RT-PCR [59]. They stated that 2019-nCov does not infect the" exact="testes" post="and the virus may not be sexually transmitted by"/>
  <result pre="infected men. Some studies have shown the presence of asymptomatic" exact="viral" post="carriers with normal laboratory and chest CT findings [60,"/>
  <result pre="the presence of asymptomatic viral carriers with normal laboratory and" exact="chest" post="CT findings [60, 61]. The mechanism by which asymptomatic"/>
  <result pre="2019-nCoV. Effect of COVID-19 on Other Organs In addition to" exact="respiratory" post="illnesses, which may be associated with pneumonia, sepsis, or"/>
  <result pre="and severe symptoms in patients with COVID-19. Fig. 3 The" exact="systemic" post="disorders caused by the COVID-19 According to several studies,"/>
  <result pre="COVID-19 According to several studies, 2019-nCoV infection, similar to some" exact="viral" post="infections, may be accompanied by cardiac injury. A study"/>
  <result pre="China, found that about one-fifth of patients with COVID-19 developed" exact="heart" post="disease, which increased the mortality rate in patients [63]."/>
  <result pre="heart disease, which increased the mortality rate in patients [63]." exact="Severe" post="and sudden inflammation of the heart muscle causes arrhythmias"/>
  <result pre="rate in patients [63]. Severe and sudden inflammation of the" exact="heart" post="muscle causes arrhythmias and impairs the heartâ€™s ability to"/>
  <result pre="in patients [63]. Severe and sudden inflammation of the heart" exact="muscle" post="causes arrhythmias and impairs the heartâ€™s ability to efficiently"/>
  <result pre="efficiently pump blood [64]. Therefore, patients with a history of" exact="cardiovascular disease" post="and with high blood pressure are at higher risk"/>
  <result pre="pump blood [64]. Therefore, patients with a history of cardiovascular" exact="disease" post="and with high blood pressure are at higher risk"/>
  <result pre="Therefore, patients with a history of cardiovascular disease and with" exact="high blood pressure" post="are at higher risk of death than normal individuals."/>
  <result pre="are at higher risk of death than normal individuals. Oxygen" exact="deficiency" post="due to trauma in the lungs damages the lining"/>
  <result pre="to trauma in the lungs damages the lining of the" exact="heart" post="and blood vessels [65]. Besides, fatty plaques in the"/>
  <result pre="in the lungs damages the lining of the heart and" exact="blood vessels" post="[65]. Besides, fatty plaques in the arteries of the"/>
  <result pre="vessels [65]. Besides, fatty plaques in the arteries of the" exact="heart" post="of people with or without symptoms of cardiovascular disease"/>
  <result pre="of the heart of people with or without symptoms of" exact="cardiovascular disease" post="may become unstable due to fever and inflammation, leading"/>
  <result pre="the heart of people with or without symptoms of cardiovascular" exact="disease" post="may become unstable due to fever and inflammation, leading"/>
  <result pre="may become unstable due to fever and inflammation, leading to" exact="vascular" post="obstruction and cardiovascular problems [66]. Other possible disorders seen"/>
  <result pre="due to fever and inflammation, leading to vascular obstruction and" exact="cardiovascular" post="problems [66]. Other possible disorders seen in hospitalized patients"/>
  <result pre="in hospitalized patients with COVID-19 are abnormal blood clotting and" exact="venous thromboembolism," post="which necessitate the administration of anticoagulants or thromboprophylaxis for"/>
  <result pre="or vision, and decreasing alertness [68]. Also, seizures, stroke, and" exact="acute" post="necrotizing hemorrhagic encephalopathy have been reported in patients with"/>
  <result pre="decreasing alertness [68]. Also, seizures, stroke, and acute necrotizing hemorrhagic" exact="encephalopathy" post="have been reported in patients with severe COVID-19 infection"/>
  <result pre="hemorrhagic encephalopathy have been reported in patients with severe COVID-19" exact="infection" post="[69]. Therapeutic results have shown that neurological symptoms gradually"/>
  <result pre="have shown that neurological symptoms gradually decrease in patients receiving" exact="viral encephalitis" post="treatment [70]. About half of patients with COVID-19 show"/>
  <result pre="shown that neurological symptoms gradually decrease in patients receiving viral" exact="encephalitis" post="treatment [70]. About half of patients with COVID-19 show"/>
  <result pre="all patients suffer from vomiting, diarrhea, and other gastrointestinal disorders." exact="Acute" post="viral hepatitis has also been found in some of"/>
  <result pre="patients suffer from vomiting, diarrhea, and other gastrointestinal disorders. Acute" exact="viral hepatitis" post="has also been found in some of these patients"/>
  <result pre="suffer from vomiting, diarrhea, and other gastrointestinal disorders. Acute viral" exact="hepatitis" post="has also been found in some of these patients"/>
  <result pre="connect gastrointestinal disorders with COVID-19. Treatment of the COVID-19 Most" exact="viral" post="infections target a series of â€œprotective responsesâ€� in the"/>
  <result pre="gastrointestinal disorders with COVID-19. Treatment of the COVID-19 Most viral" exact="infections" post="target a series of â€œprotective responsesâ€� in the host"/>
  <result pre="people or patients with immunodeficiency, lung problems such as fibrosis," exact="chronic" post="obstruction and asthma, cardiovascular and hypertension problems, diabetics, or"/>
  <result pre="immunodeficiency, lung problems such as fibrosis, chronic obstruction and asthma," exact="cardiovascular" post="and hypertension problems, diabetics, or obesity. Such infected people"/>
  <result pre="problems such as fibrosis, chronic obstruction and asthma, cardiovascular and" exact="hypertension" post="problems, diabetics, or obesity. Such infected people may encounter"/>
  <result pre="people may encounter more severe symptoms of the disease, severe" exact="respiratory" post="problems, and even death [76â€&quot;78]. Weak immune responses and"/>
  <result pre="immune responses and inability to fight the virus increase the" exact="viral" post="load, leading to increased secretion of inflammatory cytokine in"/>
  <result pre="severe inflammatory/oxidative stress response, followed by severe lung damage. Considering" exact="acute" post="respiratory distress syndrome, antiviral therapy, antibiotics, corticosteroids, and anti-inflammatory"/>
  <result pre="inflammatory/oxidative stress response, followed by severe lung damage. Considering acute" exact="respiratory" post="distress syndrome, antiviral therapy, antibiotics, corticosteroids, and anti-inflammatory drugs"/>
  <result pre="corticosteroids and interferons), monoclonal antibody production, and inhibitory agents against" exact="viral" post="proteinase, helicase, and polymerases [80]. However, to date, no"/>
  <result pre="has been approved by the FDA for COVID-19. Due to" exact="short" post="replication times and high viral yields, the replication of"/>
  <result pre="FDA for COVID-19. Due to short replication times and high" exact="viral" post="yields, the replication of the positive-sense viral RNA genome"/>
  <result pre="times and high viral yields, the replication of the positive-sense" exact="viral" post="RNA genome undergoes high error rates and homologous and"/>
  <result pre="anti-COVID-19 drug and vaccine [81, 82]. Clinical control of the" exact="disease" post="is only based on symptoms via available therapeutic drugs,"/>
  <result pre="Azithromycin, Ascorbic acid, Nitric oxide, Corticosteroids, IL-6 antagonists. Because the" exact="viral" post="load reaches its peak around the time of symptom"/>
  <result pre="and may be effective in reducing the severity of the" exact="disease" post="and the duration of the viral infection [83]. Vitamin"/>
  <result pre="the severity of the disease and the duration of the" exact="viral infection" post="[83]. Vitamin D as an adjunctive agent can reduce"/>
  <result pre="severity of the disease and the duration of the viral" exact="infection" post="[83]. Vitamin D as an adjunctive agent can reduce"/>
  <result pre="D as an adjunctive agent can reduce the risk of" exact="viral" post="infections and prevent pneumonia and lung damage through a"/>
  <result pre="as an adjunctive agent can reduce the risk of viral" exact="infections" post="and prevent pneumonia and lung damage through a variety"/>
  <result pre="agent can reduce the risk of viral infections and prevent" exact="pneumonia" post="and lung damage through a variety of mechanisms, including"/>
  <result pre="the IgG1Ï&quot; subclass. At first, it was used to treat" exact="rheumatoid arthritis" post="and juvenile idiopathic arthritis. Then, it was administered against"/>
  <result pre="IgG1Ï&quot; subclass. At first, it was used to treat rheumatoid" exact="arthritis" post="and juvenile idiopathic arthritis. Then, it was administered against"/>
  <result pre="At first, it was used to treat rheumatoid arthritis and" exact="juvenile idiopathic arthritis." post="Then, it was administered against cytokine storms in coronavirus"/>
  <result pre="it was administered against cytokine storms in coronavirus and influenza" exact="infections" post="that are characterized by high levels of IL-6 and"/>
  <result pre="cytokines. Actemra successfully could diminish the cytokine storm associated with" exact="viral" post="infections. Tian et al. in their research proposed that"/>
  <result pre="for more than 70â€‰years and also as anti-amoebiosis and anti-human" exact="immunodeficiency" post="virus. In-vitro and small clinical studies have shown that"/>
  <result pre="have shown that both drugs could be effective against SARS-CoV" exact="infection" post="and prevent from the virus spread [88], but several"/>
  <result pre="chloroquine and hydroxychloroquine is associated with an increased risk of" exact="heart" post="problems in COVID-19 patients, including cardiac arrhythmias and cardiac"/>
  <result pre="of heart problems in COVID-19 patients, including cardiac arrhythmias and" exact="cardiac arrest" post="[89]. In addition to chemical drugs, traditional herbal medicines"/>
  <result pre="COVID-19 patients and they claimed that it could prevent the" exact="disease" post="from getting worse and reduce the symptoms of the"/>
  <result pre="positive reports of this herbal formula in the treatment of" exact="lung diseases" post="in our country, no experimental or clinical reports were"/>
  <result pre="is used to improve the immune system and to treat" exact="pulmonary" post="symptoms caused by bacterial infections [96]. Despite such treatments,"/>
  <result pre="the immune system and to treat pulmonary symptoms caused by" exact="bacterial infections" post="[96]. Despite such treatments, there are few reports of"/>
  <result pre="immune system and to treat pulmonary symptoms caused by bacterial" exact="infections" post="[96]. Despite such treatments, there are few reports of"/>
  <result pre="RNA, although a small portion of discharged COVID-19 has shown" exact="recurrent" post="recurrences. There are reports of improved people that showed"/>
  <result pre="they may still be a virus carrier and spread the" exact="infection" post="to others. Conclusions 2019-nCoV exists in the respiratory, fecal,"/>
  <result pre="However, the main route of transmission is through inhalation of" exact="respiratory" post="droplets or contact with contaminated fomites due to the"/>
  <result pre="the weather warms up in the summer and the 2019-nCoV" exact="infection" post="is predicted to start again with the gradual cooling"/>
  <result pre="successful drugs and vaccines against 2019-nCoV infection. However, in the" exact="absence of" post="vaccines and antivirals, the most important way to control"/>
  <result pre="vaccines and antivirals, the most important way to control the" exact="disease" post="among the populations is regular hand washing, the use"/>
  <result pre="interacting with the infected environment. Abbreviations COVID-19 Coronavirus disease-19 SARS-CoV-2" exact="Severe" post="acute respiratory syndrome coronavirus 2 2019-nCoV Novel coronavirus ACE"/>
  <result pre="with the infected environment. Abbreviations COVID-19 Coronavirus disease-19 SARS-CoV-2 Severe" exact="acute" post="respiratory syndrome coronavirus 2 2019-nCoV Novel coronavirus ACE Angiotensin-converting"/>
  <result pre="the infected environment. Abbreviations COVID-19 Coronavirus disease-19 SARS-CoV-2 Severe acute" exact="respiratory" post="syndrome coronavirus 2 2019-nCoV Novel coronavirus ACE Angiotensin-converting enzyme"/>
  <result pre="infected environment. Abbreviations COVID-19 Coronavirus disease-19 SARS-CoV-2 Severe acute respiratory" exact="syndrome" post="coronavirus 2 2019-nCoV Novel coronavirus ACE Angiotensin-converting enzyme MERS-CoV"/>
  <result pre="2 2019-nCoV Novel coronavirus ACE Angiotensin-converting enzyme MERS-CoV Middle East" exact="Respiratory" post="Syndrome Coronavirus RBD Receptor-binding domain ACE2 Angiotensin-converting enzyme 2"/>
  <result pre="2019-nCoV Novel coronavirus ACE Angiotensin-converting enzyme MERS-CoV Middle East Respiratory" exact="Syndrome" post="Coronavirus RBD Receptor-binding domain ACE2 Angiotensin-converting enzyme 2 Publisherâ€™s"/>
  <result pre="important research questionsCell Biosci2020104032190290 2.SchettGSticherlingMNeurathMFCOVID-19: risk for cytokine targeting in" exact="chronic" post="inflammatory diseases?Nat Rev Immunol202020527127232296135 3.Lovato A, de Filippis C,"/>
  <result pre="de Filippis C, Marioni G. Upper airway symptoms in coronavirus" exact="disease" post="2019 (COVID-19). Am J Otolaryngol. 2020:102474. 4.Paranjpe I, Russak"/>
  <result pre="al.Detection of IgM and IgG antibodies in patients with coronavirus" exact="disease" post="2019Clin Transl Immunol202095e01136 10.Jacofsky D, Jacofsky EM, Jacofsky M."/>
  <result pre="2019Clin Transl Immunol202095e01136 10.Jacofsky D, Jacofsky EM, Jacofsky M. Understanding" exact="Antibody" post="Testing for COVID-19. J Arthroplasty. 2020. 11.SinghalTA Review of"/>
  <result pre="13.Comas-GarciaMPackaging of Genomic RNA in Positive-Sense Single-Stranded RNA Viruses: A" exact="Complex" post="StoryViruses.2019113253 14.MousavizadehLGhasemiSGenotype and phenotype of COVID-19: Their roles in"/>
  <result pre="Microbiol Immunol Infect.2020S1684â€&quot;182203008230087 15.VelavanTPMeyerCGThe COVID-19 epidemicTrop Med Int Health.202025327828032052514 16.LiHLiuS-MYuX-HTangS-LTangC-KCoronavirus" exact="disease" post="2019 (COVID-19): current status and future perspectivesInt J Antimicrob"/>
  <result pre="al.Ezrin interacts with the SARS coronavirus Spike protein and restrains" exact="infection" post="at the entry stagePLoS One.2012711e4956623185364 20.HuiDSMemishZAZumlaASevere acute respiratory syndrome"/>
  <result pre="protein and restrains infection at the entry stagePLoS One.2012711e4956623185364 20.HuiDSMemishZAZumlaASevere" exact="acute" post="respiratory syndrome vs. the Middle East respiratory syndromeCurr Opin"/>
  <result pre="and restrains infection at the entry stagePLoS One.2012711e4956623185364 20.HuiDSMemishZAZumlaASevere acute" exact="respiratory" post="syndrome vs. the Middle East respiratory syndromeCurr Opin Pulm"/>
  <result pre="restrains infection at the entry stagePLoS One.2012711e4956623185364 20.HuiDSMemishZAZumlaASevere acute respiratory" exact="syndrome" post="vs. the Middle East respiratory syndromeCurr Opin Pulm Med.201420323324124626235"/>
  <result pre="stagePLoS One.2012711e4956623185364 20.HuiDSMemishZAZumlaASevere acute respiratory syndrome vs. the Middle East" exact="respiratory" post="syndromeCurr Opin Pulm Med.201420323324124626235 21.PetrosilloNViceconteGErgonulOIppolitoGPetersenECOVID-19, SARS and MERS: are"/>
  <result pre="SARS and MERS: are they closely related?Clin Microbiol Infect.202026672973432234451 22.LaiCCShihTPKoWCTangHJHsuehPRSevere" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19):"/>
  <result pre="and MERS: are they closely related?Clin Microbiol Infect.202026672973432234451 22.LaiCCShihTPKoWCTangHJHsuehPRSevere acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The"/>
  <result pre="MERS: are they closely related?Clin Microbiol Infect.202026672973432234451 22.LaiCCShihTPKoWCTangHJHsuehPRSevere acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic"/>
  <result pre="One Assay Kit. J Clin Microbiol. 2020;58(6). 24.YanCCuiJHuangLDuBChenLXueGet al.Rapid and" exact="visual" post="detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse"/>
  <result pre="the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long" exact="Structural" post="Studies of SARS Coronavirus. J Virol. 2020;94(7). 26.YanTXiaoRLinGAngiotensin-converting enzyme"/>
  <result pre="SARS Coronavirus. J Virol. 2020;94(7). 26.YanTXiaoRLinGAngiotensin-converting enzyme 2 in severe" exact="acute" post="respiratory syndrome coronavirus and SARS-CoV-2: A double-edged sword?Faseb j.20203456017602632306452"/>
  <result pre="Coronavirus. J Virol. 2020;94(7). 26.YanTXiaoRLinGAngiotensin-converting enzyme 2 in severe acute" exact="respiratory" post="syndrome coronavirus and SARS-CoV-2: A double-edged sword?Faseb j.20203456017602632306452 27.Rettner"/>
  <result pre="J Virol. 2020;94(7). 26.YanTXiaoRLinGAngiotensin-converting enzyme 2 in severe acute respiratory" exact="syndrome" post="coronavirus and SARS-CoV-2: A double-edged sword?Faseb j.20203456017602632306452 27.Rettner R."/>
  <result pre="M, et al. Pathological study of the 2019 novel coronavirus" exact="disease" post="(COVID-19) through postmortem core biopsies. Mod Pathol. 33(6):1007-14. 30.Belen-Apak"/>
  <result pre="postmortem core biopsies. Mod Pathol. 33(6):1007-14. 30.Belen-Apak FB, SarÄ±alioÄŸlu F." exact="Pulmonary" post="intravascular coagulation in COVID-19: possible pathogenesis and recommendations on"/>
  <result pre="Thromb Thrombolysis. 50(2):278-80. 31.XuZShiLWangYZhangJHuangLZhangCet al.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir Med.20208442042232085846 32.CampbellRASchwertzHHottzEDRowleyJWManneBKWashingtonAVet al.Human megakaryocytes possess"/>
  <result pre="Thrombolysis. 50(2):278-80. 31.XuZShiLWangYZhangJHuangLZhangCet al.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir Med.20208442042232085846 32.CampbellRASchwertzHHottzEDRowleyJWManneBKWashingtonAVet al.Human megakaryocytes possess intrinsic"/>
  <result pre="immunity through regulated induction of IFITM3Blood.2019133192013202630723081 33.Li Y, Xiao SY." exact="Hepatic" post="involvement in COVID-19 patients: Pathology, pathogenesis, and clinical implications."/>
  <result pre="ACE2/ACE balance and pneumocyte apoptosis in a porcine model of" exact="acute" post="pulmonary thromboembolism with cardiac arrestMol Med Rep.20181734221422829328448 38.Tikellis C,"/>
  <result pre="balance and pneumocyte apoptosis in a porcine model of acute" exact="pulmonary" post="thromboembolism with cardiac arrestMol Med Rep.20181734221422829328448 38.Tikellis C, Thomas"/>
  <result pre="and ACE Inhibitor and ARB Use during the Pandemic: The" exact="Pediatric" post="Perspective. Hypertension. 2020;76(1):16-22. 40.Zolfaghari EmamehRFalakRBahreiniEApplication of System Biology to"/>
  <result pre="and possibly pathophysiologic role in inflammation with special effect on" exact="respiratory" post="inflammationAllergy.19985311102310429860235 42.CampbellDJNeprilysin Inhibitors and BradykininFront Med (Lausanne)2018525730283782 43.SerfozoPWysockiJGuluaGSchulzeAYeMLiuPet al.Ang"/>
  <result pre="COVID-19 outbreak. Curr Biol. 2020. 51.SpiteriGFieldingJDierckeMCampeseCEnoufVGaymardAet al.First cases of coronavirus" exact="disease" post="2019 (COVID-19) in the WHO European Region, 24 January"/>
  <result pre="Li W, Hu B, Chen G, Xia P, et al." exact="Absence of" post="2019 Novel Coronavirus in Semen and Testes of COVID-19"/>
  <result pre="of COVID-19 Patients. Biol Reprod. 2020:ioaa050. 60.LaiC-CLiuYHWangC-YWangY-HHsuehS-CYenM-Yet al.Asymptomatic carrier state," exact="acute" post="respiratory disease, and pneumonia due to severe acute respiratory"/>
  <result pre="COVID-19 Patients. Biol Reprod. 2020:ioaa050. 60.LaiC-CLiuYHWangC-YWangY-HHsuehS-CYenM-Yet al.Asymptomatic carrier state, acute" exact="respiratory" post="disease, and pneumonia due to severe acute respiratory syndrome"/>
  <result pre="Reprod. 2020:ioaa050. 60.LaiC-CLiuYHWangC-YWangY-HHsuehS-CYenM-Yet al.Asymptomatic carrier state, acute respiratory disease, and" exact="pneumonia" post="due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2):"/>
  <result pre="carrier state, acute respiratory disease, and pneumonia due to severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and mythsJ Microbiol"/>
  <result pre="state, acute respiratory disease, and pneumonia due to severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2): Facts and mythsJ Microbiol Immunol"/>
  <result pre="acute respiratory disease, and pneumonia due to severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2): Facts and mythsJ Microbiol Immunol Infect.2020S1684â€&quot;182203004030042"/>
  <result pre="Cai Y, Liu T, Yang F, et al. Association of" exact="Cardiac" post="Injury With Mortality in Hospitalized Patients With COVID-19 in"/>
  <result pre="2020;5(7):802â€&quot;10. 64.ZhuHRheeJWChengPWalianySChangAWittelesRMet al.Cardiovascular Complications in Patients with COVID-19: Consequences of" exact="Viral" post="Toxicities and Host Immune ResponseCurr Cardiol Rep.20202253232318865 65.RizzoPVieceli Dalla"/>
  <result pre="Host Immune ResponseCurr Cardiol Rep.20202253232318865 65.RizzoPVieceli Dalla SegaFFortiniFMarracinoLRapezziCFerrariRCOVID-19 in the" exact="heart" post="and the lungs: could we â€œNotchâ€� the inflammatory storm?Basic"/>
  <result pre="action. Br J Haematol. 2020;189(5):846-7. 68.WuYXuXChenZDuanJHashimotoKYangLet al.Nervous system involvement after" exact="infection" post="with COVID-19 and other coronavirusesBrain Behav Immun.2020S0889â€&quot;1591203035730353 69.Wu X,"/>
  <result pre="Wu W, Pan W, Wu L, Liu K, Zhang H-L." exact="Acute" post="necrotizing encephalopathy: an underrecognized clinicoradiologic disorder. Mediators Inflamm. 2015;2015:792578."/>
  <result pre="clinicoradiologic disorder. Mediators Inflamm. 2015;2015:792578. 70.WuYXuXChenZDuanJHashimotoKYangLet al.Nervous system involvement after" exact="infection" post="with COVID-19 and other coronavirusesBrain Behav Immun.202087182232240762 71.Larsen CP,"/>
  <result pre="O, MdA S. Collapsing Glomerulopathy in a Patient With Coronavirus" exact="Disease" post="2019 (COVID-19). Kidney Int Rep. 2020. 10.1016/j.ekir.2020.04.002. 72.ChengYLuoRWangKZhangMWangZDongLet al.Kidney"/>
  <result pre="Collapsing Glomerulopathy in a Patient With Coronavirus Disease 2019 (COVID-19)." exact="Kidney" post="Int Rep. 2020. 10.1016/j.ekir.2020.04.002. 72.ChengYLuoRWangKZhangMWangZDongLet al.Kidney disease is associated"/>
  <result pre="Disease 2019 (COVID-19). Kidney Int Rep. 2020. 10.1016/j.ekir.2020.04.002. 72.ChengYLuoRWangKZhangMWangZDongLet al.Kidney" exact="disease" post="is associated with in-hospital death of patients with COVID-19Kidney"/>
  <result pre="with in-hospital death of patients with COVID-19Kidney Int.202097582983832247631 73.DurvasulaRWellingtonTMcNamaraEWatnickSCOVID-19 and" exact="Kidney" post="Failure in the Acute Care Setting: Our Experience From"/>
  <result pre="in-hospital death of patients with COVID-19Kidney Int.202097582983832247631 73.DurvasulaRWellingtonTMcNamaraEWatnickSCOVID-19 and Kidney" exact="Failure" post="in the Acute Care Setting: Our Experience From SeattleAm"/>
  <result pre="patients with COVID-19Kidney Int.202097582983832247631 73.DurvasulaRWellingtonTMcNamaraEWatnickSCOVID-19 and Kidney Failure in the" exact="Acute" post="Care Setting: Our Experience From SeattleAm J Kidney Dis.2020S0272â€&quot;6386203061830611"/>
  <result pre="in the Acute Care Setting: Our Experience From SeattleAm J" exact="Kidney" post="Dis.2020S0272â€&quot;6386203061830611 74.GuJHanBWangJCOVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral TransmissionGastroenterology.202015861518151932142785 75.Ding"/>
  <result pre="interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in" exact="lupus" post="patients. Clin Immun. 2020;108410. 79.GattinoniLCoppolaSCressoniMBusanaMRossiSChiumelloDCovid-19 does not lead to"/>
  <result pre="Clin Immun. 2020;108410. 79.GattinoniLCoppolaSCressoniMBusanaMRossiSChiumelloDCovid-19 does not lead to a â€œtypicalâ€�" exact="acute" post="respiratory distress syndromeAm J Resp Crit Care Med2020201101299130032228035 80.Perales"/>
  <result pre="Immun. 2020;108410. 79.GattinoniLCoppolaSCressoniMBusanaMRossiSChiumelloDCovid-19 does not lead to a â€œtypicalâ€� acute" exact="respiratory" post="distress syndromeAm J Resp Crit Care Med2020201101299130032228035 80.Perales C,"/>
  <result pre="for the 2019-new coronavirus (2019-nCoV)Biosci Trends.2020141697131996494 83.HeXLauEHWuPDengXWangJHaoXet al.Temporal dynamics in" exact="viral" post="shedding and transmissibility of COVID-19Nat Med202026567267532296168 84.PanareseAShahiniECovid-19, and vitamin"/>
  <result pre="Med202026567267532296168 84.PanareseAShahiniECovid-19, and vitamin DAlimentary Pharmacol Ther20205110993 85.SkalnyAVRinkLAjsuvakovaOPAschnerMGritsenkoVAAlekseenkoSIet al.Zinc and" exact="respiratory" post="tract infections: Perspectives for COVID-19Int J Mol Med2020461172632319538 86.Seftel"/>
  <result pre="Infect.20209138238532065055 88.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGet al.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J200526916115318 89.SinghAKSinghAShaikhASinghRMisraAChloroquine and hydroxychloroquine in the treatment"/>
 </snippets>
</snippetsTree>
